Annovis Bio (ANVS) AI Stock Analysis

• Market Cap: $50.86M
• Dividend Yield: N/A
• Average Volume (3M): 287.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.76
• Revenue Growth: N/A
• EPS Growth: 54.85%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 19,486,230
• 10 Day Avg. Volume: 260,819
• 30 Day Avg. Volume: 287,685
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $10.00
• Price Target Upside: 321.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 35 Underperform
• Price Target: ―

Annovis Bio's overall stock score reflects significant financial challenges with zero revenue and consistent losses, offset slightly by a debt-free balance sheet. Technical indicators suggest a bearish outlook, and valuation metrics are unattractive. Corporate events create a mixed picture, with regulatory compliance issues countered by progress in drug development. The stock remains speculative, relying heavily on future R&D success.

Positive Factors

Clinical Trials

The pivotal P3 study for buntanetap is ongoing and enrolling, with over 400 patients screened and 38 randomized to buntanetap or placebo.

Intellectual Property

Annovis announced the completion of patent transfer to the crystalline form of buntanetap, extending the IP estate around both forms of the drug to 2046.

Regulatory Approval

Annovis Bio previously held an end-of-Phase 2 (EOP2) meeting with the FDA, in which the agency granted clearance to Annovis Bio to proceed with pivotal Phase 3 development of buntanetap, based on the company's Phase 2/3 data showing symptomatic improvement in patients with early Alzheimer's disease.

Negative Factors

Dilution Risk

Factoring in dilution from the financing lowers the 12-month price target to $8, from $25.

Financial Performance

The 12-month price target is reduced to $12 from the prior $30 per share to reflect the impact of the most recent equity financing, future potential equity issuances, and the exercise of warrants.

Market Risks

Broad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.

Annovis Bio Business Overview & Revenue Model

Company Description

Annovis Bio (ANVS) is a clinical-stage pharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company is primarily engaged in the research and development of drugs aimed at treating conditions such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative disorders. Annovis Bio is committed to creating solutions that can halt or reverse the progression of these debilitating diseases by targeting the underlying biological pathways involved in neurodegeneration.

How the Company Makes Money

Annovis Bio generates revenue primarily through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials and eventually receiving regulatory approval for commercialization. Once a drug is approved, Annovis Bio may earn money through direct sales, licensing agreements, or partnerships with larger pharmaceutical companies for distribution and marketing. Additionally, the company may also receive funding from grants or collaborative research agreements with other institutions. However, as a clinical-stage company, Annovis Bio may not currently have significant revenue streams from commercialized products.

Annovis Bio Financial Statement Overview

Summary

Annovis Bio's financial performance is weak due to zero revenue and increasing net losses, which is common for early-stage biotech firms. The balance sheet is hampered by negative equity at times, despite having no debt. Cash flows are negative, indicating reliance on external funding.

Income Statement

Annovis Bio has reported zero revenue consistently since 2019, which is a significant concern for sustainability. The company has faced increasing net losses, with the latest annual report showing a net loss of approximately $24.59 billion. The lack of revenue and growing losses reflect poor financial health from an income perspective, typical for early-stage biotechnology firms focusing on R&D without a commercialized product.

Balance Sheet

The balance sheet shows that Annovis Bio has no debt, which is a positive sign. However, the company has a negative equity at times and fluctuating stockholders' equity, indicating financial instability. The equity ratio has been erratic, and the lack of tangible revenue-generating assets further complicates its financial stability.

Cash Flow

Operating cash flows have been consistently negative, reflecting the company's ongoing investments in operations without incoming cash flow from sales. While financing activities have provided some relief, the overall cash flow situation highlights a dependency on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-23.63M	-22.74M	-45.03M	-25.33M	-14.50M	-5.46M
Net Income	-30.26M	-24.59B	-56.20M	-25.33M	-14.49M	-5.46M
Balance Sheet
Total Assets	21.45B	13.93M	10.21M	36.02M	46.00M	8.12M
Cash, Cash Equivalents and Short-Term Investments	17.13B	10.55M	5.75M	28.38M	45.69M	8.07M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	3.12B	4.62M	17.96M	7.70M	1.51M	578.38K
Stockholders Equity	18.33B	9.31M	-7.75M	28.32M	44.49M	7.54M
Cash Flow
Free Cash Flow	-13.22B	-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
Operating Cash Flow	-13.22B	-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	37.82M	26.69B	17.34M	4.61K	46.74M	12.04M

Annovis Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.37
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 2.37 is below the 20-day moving average (MA) of 2.65, below the 50-day MA of 2.63, and below the 200-day MA of 3.29, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.51 is Neutral, neither overbought nor oversold. The STOCH value of 11.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.

Annovis Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	CHF27.85B	4.56	9.71%	2.05%	17.36%	-33.07%
GBIO	50 Neutral	$43.04M	―	-85.45%	―	61.15%	54.71%
PYPD	41 Neutral	$35.46M	―	-312.77%	―	―	61.18%
INKT	38 Underperform	$67.62M	―	78.50%	―	―	41.90%
BCAB	35 Underperform	$21.00M	―	-813.88%	―	―	49.48%
ANVS	35 Underperform	$50.86M	―	-365.03%	―	―	54.85%

Annovis Bio Corporate Events

Annovis Bio Faces NYSE Non-Compliance Notice

On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with the NYSE’s continued listing standards due to its average market capitalization and stockholders’ equity falling below $50 million. The company plans to submit a compliance plan within 45 days, which the NYSE will review to determine if Annovis can meet the standards within an 18-month period. The notice does not affect the company’s business operations or its reporting obligations, and its stock will continue to be traded with a ‘.BC’ designation until compliance is regained.

Annovis Bio Launches Phase 3 Alzheimer’s Study

On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.